Bintrafusp alfa, a first-in-class bifunctional fusion protein, demonstrated promising clinical efficacy and a well-tolerated safety profile in pre-treated NSCLC patients with anti-PD-L1 antibodies, achieved by PD-L1 blockade and TGF-β entrapment [340]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.